Phase Ib Study: Venetoclax With or Without Azacitidine for Treatment of Relapsed/Refractory Myelodysplastic Syndrome

December 7-10, 2019; Orlando, Florida
Venetoclax alone or in combination with azacitidine was well tolerated in patients with relapsed/refractory MDS, with combination therapy achieving an ORR of 40% and estimated 12-month OS of 65%.
Format: Microsoft PowerPoint (.ppt)
File Size: 236 KB
Released: December 19, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Commentary from Dr Julie M. Vose on how to select therapy for patients with diffuse large B-cell lymphoma, from Clinical Care Options (CCO)

Julie M. Vose, MD, MBA Released: December 1, 2021

person default Ashley Leak Bryant, PhD, RN, OCN, FAAN Sara Tinsley, PhD, APRN, AOCN Released: November 29, 2021

Downloadable short slideset from CCO on recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021

Amer M. Zeidan, MBBS, discusses novel and investigational therapies for treating patients with myelodysplastic syndromes (MDS) in this commentary from Clinical Care Options (CCO)

Amer Zeidan, MBBS Released: November 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue